Missense mutations leading to ***** inactivation may also be sensitive to therapies that reactivate mutant ***** such as *****-246 (***** et al., 2016; ***** Abstract 5571, ***** et al., 2012; *****, ***** et al., 2015; *****, ***** al., 2016; *****).
